

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

Claim 1. (Currently amended) A topical pharmaceutical composition, comprising a topically acceptable carrier, and a therapeutically effective amount of at least one cyclic psychotropic agent for treating a benign hyperproliferative skin disorder associated with excessive proliferation of skin cells, wherein the at least one cyclic psychotropic agent being other than doxepine and tomoxetine, is selected from the group consisting of an antidepressant agent and an antipsychotic agent.

Claim 2. (Previously presented) The composition according to claim 1, wherein the at least one cyclic psychotropic agent comprises at least one anti-depressant agent.

Claim 3. (Previously presented) The composition according to claim 2, wherein the at least one anti-depressant agent is selected from the group consisting of a selective serotonin re-uptake inhibitor (SSRI); a selective noradrenaline re-uptake inhibitor (NRIS); a serotonin and noradrenergic re-uptake inhibitor (SNRI); a cyclic anti-depressant; and an atypical anti-depressant.

Claim 4. (Currently amended) The composition according to claim 3, wherein:

- (a) the SSRI is selected from the group consisting of fluoxetine, paroxetine and sertraline;
- (b) the NRIS is reboxetine
- (c) the SNRI is selected from the group consisting of venlafaxine, duloxetine and milnacipran;
- (d) the cyclic anti-depressant is selected from the group consisting of
 - (d1) a tricyclic anti-depressant selected from the group consisting of imipramine, clomipramine, amitriptyline and doxepine;
 - (d2) a bicyclic anti-depressant selected from the group consisting of paroxetine, and sertraline;
 - (d3) a monocyclic anti-depressant comprising a phenylpropylamine derivative compound; and
 - (d4) an atypical anti-depressant selected from the group consisting of mianserin, bupropion, mirtazapine, and trazodone.

Claim 5. (Currently amended) The composition according to claim 4, wherein the phenylpropylamine derivative compound is a phenoxy-3-propylamine derivative.

Claim 6. (Previously presented) The composition according to claim 5, wherein the phenoxy-3 propylamine derivative is selected from the group consisting of nisooxetine, fluoxetine, norfluoxetine, reboxetine, atomoxetine and venlafaxine.

Claim 7. (Currently amended) The composition according to claim 1, wherein the at least one cyclic psychotropic agent comprises at least one anti-psychotic drug.

Claim 8. (Previously presented) The composition according to claim 7, wherein the at least one anti-psychotic drug is selected from the group consisting of an tricyclic anti-psychotic drug and an atypical antipsychotic drug.

Claim 9. (Currently amended) The composition according to claim 8, wherein the tricyclic anti-psychotic drug is a phenothiazine compound.

Claim 10. (Currently amended) The composition according to claim 9, wherein the phenothiazine compound is selected from the group consisting of thioridazine, perphenazine, trifluoperazine and fluphenazine.

Claim 11. (Currently amended) The composition according to claim 8, wherein the tricyclic antipsychotic drug is a thioxanthene compound.

Claim 12. (Currently amended) The composition according to claim 11, wherein the thioxanthene compound is selected from the group consisting of flupenthixol, thiothixene, chlorprothixene and zuclopentihixol.

Claim 13. (Previously presented) The composition according to claim 8, wherein the atypical anti-psychotic drug is selected from the group consisting of clozapine, quetiapine, ziprazidone, olanzapine and risperidone.

Claim 14. (Previously presented)] The composition according to claim 1, comprising a formulation selected from the group consisting of an ointment, a cream, a gel, a solution, a suspension, a lotion, a shampoo, a foam, a lyposomic formulation, a paste, an emulsion, a salve, suppositories, vaginal tablets, ocular salves or drops, otic drops, nasal spray and nasal drops.

Claim 15. (Previously presented) The composition according to claim 14, comprising a formulation selected from the group consisting of a cream, an ointment, a gel, a foam, a solution, and a lotion.

Claim 16. (Withdrawn) A method for the treatment of a dermatological disease, disorder, or pathology the method comprising, topically administering to a subject in need of dermatological treatment, a therapeutically effective amount of a psychotropic cyclic agent, said cyclic psychotropic agent being other than atomoxetine and doxepine.

Claim 17. (Withdrawn) A method for the treatment of hyper-proliferative dermatological diseases, disorders or pathological conditions, comprising topically administering to a subject, in need of such treatment, a therapeutically effective amount of a cyclic psychotropic agent,

wherein, where the hyper-proliferative skin disorder is psoriasis, the cyclic psychotropic agent is not atomoxetine.

Claim 18. (Withdrawn) A method according to Claim 17, wherein said hyperproliferative skin disease or disorder is selected from: psoriasis, scleroderma, epidermal hyperplasia, hyperkeratosis, acanthosis, papilloma, actinic keratoses, and skin cancer.

Claim 19. (Withdrawn) The method according to Claim 18, wherein said skin cancer is selected from basal cell carcinoma, melanoma, squamous cell carcinoma, cutaneous T-cell lymphoma and Kaposi's sarcoma.

Claim 20. (Withdrawn) The method according to Claim 17, wherein the cyclic psychotropic agent is an anti-depressant.

Claim 21. (Withdrawn) The method according to Claim 20, wherein the anti-depressant is selected from: selective serotonin re-uptake inhibitor (SSRI); selective noradrenaline re-uptake inhibitor (NRIS), serotonin and noradrenergic re-uptake inhibitor (SNRI); cyclic anti-depressants, and atypical anti-depressant.

Claim 22. (Withdrawn) The method according to Claim 21, wherein:

- (e) the SSRI is selected from fluoxetine, paroxetine and sertraline;
- (f) the NRIS is selected from: atomoxetine and reboxetine;
- (g) the SNRI is selected from venlafaxine, duloxetine and milnacipran;
- (h) the cyclic anti-depressant is selected from:
 - (d1) tricyclic anti-depressant selected from: imipramine, clomipramine, amitriptyline and doxepine;
 - (d2) bicyclic anti-depressants selected from: paroxetine, sertraline and citalopram;
 - (d3) monocyclic anti-depressants selected from: phenylpropyl derivatives, fluoxetine and norfluoxetine
 - (d4) atypical anti-depressants selected from: mianserin, bupropion, mirtazapine and trazodone.

Claim 23. (Withdrawn) The method according to Claim 22, wherein the phenylpropylamine derivatives are phenoxy-3-propylamine derivatives.

Claim 24. (Withdrawn) The method according to Claim 23, wherein the phenoxy-3-propylamine derivatives are selected from: atomoxetine, nisoxetine, fluoxetine, norfluoxetine, reboxetine and venlafaxine.

Claim 25. (Withdrawn) The method according to Claim 17, wherein the cyclic psychotropic agent is an anti-psychotic drug.

Claim 26. (Withdrawn) The method according to Claim 25, wherein the anti-psychotic drug is selected from tricyclic anti-psychotic drug and atypical antipsychotic drug.

Claim 27. (Withdrawn) The method according to Claim 26, wherein the tricyclic anti-psychotic drug is phenothiazine.

Claim 28. (Withdrawn) The method according to Claim 27, wherein the phenothiazine is selected from: thioridazine, perphenazine, trifluoperazine and fluphenazine.

Claim 29. (Withdrawn) The method according to Claim 26, wherein the tricyclic antipsychotic drug is thioxanthenes.

Claim 30. (Withdrawn) The method according to Claim 29, wherein the thioxanthenes are selected from flupenthixol, thiothixene, chlorprothixene and zuclopentihixol.

Claim 31. (Withdrawn) The method according to Claim 26, wherein the atypical anti-psychotic drug is selected from clozapine, quetiapine, ziprazidone, olanzapine and risperidone.

Claim 32. (Withdrawn) A method for the treatment of an inflammatory dermatological disease, disorder or pathological condition comprising topically administering to a subject, in need of such treatment, a therapeutically effective amount of a cyclic psychotropic agent,

wherein, where the inflammatory skin disorder, disease or pathological condition is manifested by pruritus, the cyclic psychotropic agent is not doxepine.

Claim 33. (Withdrawn) A method according to claim 32 wherein, where the inflammatory skin disorder, disease or pathological condition is manifested by pruritus, or the skin disorder is atopic dermatitis the cyclic psychotropic agent is not doxepine.

Claim 34. (Withdrawn) A method according to Claim 33, wherein the inflammatory disease, disorder or pathological condition is an autoimmune disease.

Claim 35. (Withdrawn) A method according to Claim 34, wherein said autoimmune skin disorder is selected from: vitiligo, scleroderma, alopecia areata, psoriatic arthritis, lichen planus, lichen sclerosus, discoid lupus, lupus erythematosus, leg ulceration in rheumatoid arthritis, atopic dermatitis, cicatrical pemphigoid and pyoderma gangrenosum.

Claim 36. (Withdrawn) A method according to Claim 34, wherein the inflammatory disease is a non-autoimmune disease.

Claim 37. (Withdrawn) A method according to Claim 36, wherein the inflammatory disease is selected from: rosacea, pruritus, seborrheic dermatitis and contact dermatitis .

Claim 38. (Withdrawn) A method according to Claim 33, wherein the cyclic psychotropic agent is an anti-depressant.

Claim 39. (Withdrawn) A method according to Claim 38, wherein the active anti-depressant is selected from: selective serotonin re-uptake inhibitor (SSRI); selective noradrenaline re-uptake inhibitor (NRIS), serotonin and noradrenergic re-uptake inhibitor (SNRI); cyclic anti-depressants, and a typical anti-depressant.

Claim 40. (Withdrawn) A method according to Claim 39, wherein:

- (i) the SSRI is selected from: fluoxetine, paroxetine, sertraline;
- (j) the NRIS is selected from: atomoxetine and reboxetine;
- (k) the SNRI is selected from: venlafaxine, duloxetine and milnacipran;
- (l) the cyclic anti-depressant selected from
 - (d1) tricyclic anti-depressant selected from imipramine, clomipramine, amitriptyline and doxepine;
 - (d2) bicyclic anti-depressants selected from paroxetine, sertraline and citalopram;
 - (d3) monocyclic anti-depressants are phenylpropylamine derivatives fluoxetine and norfluoxetine.
 - (d4) atypical anti-depressants selected from mianserin, bupropion, mirtazapine and trazodone.

Claim 41. (Withdrawn) A method according to Claim 40, wherein the phenylpropylamine derivatives are phenoxy-3-propylamine derivatives.

Claim 42. (Withdrawn) A method according to Claim 41, wherein the phenoxy-3-propylamine derivatives are selected from: atomoxetine, nisoxetine, fluoxetine, norfluoxetine, reboxetine and venlafaxine.

Claim 43. (Withdrawn) A method according to Claim 33, wherein the cyclic psychotropic agent is an anti-psychotic drug.

Claim 44. (Withdrawn) A method according to Claim 43, wherein the anti-psychotic drug is selected from tricyclic anti-psychotic drug and atypical antipsychotic drug.

Claim 45. (Withdrawn) A method according to Claim 44, wherein the tricyclic anti-psychotic drug is phenothiazine.

Claim 46. (Withdrawn) A method according to Claim 45, wherein the phenothiazine is selected from: thioridazine, perphenazine, trifluoperazine and fluphenazine.

Claim 47. (Withdrawn) A method according to Claim 43, wherein the tricyclic antipsychotic drug is thioxanthenes.

Claim 48. (Withdrawn) A method according to Claim 47, wherein the thioxanthenes are selected from flupenthixol, thiothixene, chlorprothixene and zuclopentixol

Claim 49. (Withdrawn) A method according to Claim 43, wherein the atypical anti-psychotic drug is selected from clozapine, quetiapine, ziprazidone, olanzapine and risperidone .

Claim 50. (Withdrawn) A method for sensitizing skin cancer cells to chemotoxic drugs, the method comprising topically administering to a subject, in need of chemotoxic therapy a therapeutically effective amount of a cyclic psychotropic agent, with the proviso that the cyclic psychotropic agent is not fluoxetine.

Claim 51. (Withdrawn) A method according to claim 50 wherein the skin cancer is multi-drug resistant skin cancer.

Claim 52. (Withdrawn) A method according to claim 50 wherein the cyclic psychotropic drug is topically administered simultaneously with the administration of the chemotoxic drug .

Claim 53. (Withdrawn) A method according to claim 50 wherein the cyclic psychotropic drug is topically administered prior to the administration of the chemotoxic drug.

Claim 54. (Withdrawn) A method according to claim 50 wherein the chemotoxic drug is administered systemically.

Claim 55. (Withdrawn) A method according to claim 50 wherein the cyclic psychotropic agent is a cyclic anti-psychotic drug.

Claim 56. (Withdrawn) A method according to claim 55 wherein the anti-psychotic drug is a tricyclic antipsychotic drug.

Claim 57. (Withdrawn) A method according to claim 56 wherein the tricyclic antipsychotic drug is phenothiazine.

Claim 58. (Withdrawn) A method according to Claim 57, wherein the phenothiazine is selected from: thioridazine, perphenazine, trifluoperazine and fluphenazine

Claim 59. (Withdrawn) A method for identifying and screening for , an active agent for the treatment of a dermatological/mucosal disease, disorder or pathological condition by topical or mucosal application, the method comprising:

- (a) providing one cyclic psychotropic drug as a candidate active agent;
- (b) applying the cyclic psychotropic drug to a biological model system for said dermatological/mucosal disease, disorder or pathological condition;
- (c) monitoring the change in at least one physiological parameter, said change being indicative of a beneficial therapeutic effect in said biological model system;

wherein a significant change in said at least one physiological parameter as compared to control indicates that the candidate cyclic psychotropic agent is active for the treatment of said dermatological disease, disorder or pathological condition.

Claim 60. (Withdrawn) A method according to claim 59 wherein the cyclic psychotropic drug is an anti psychotic drug or an antidepressant.

Claim 61-62. (Cancelled)

Claim 63. (Currently Amended) The composition according to claim 1 ~~62~~, wherein ~~said~~ the benign hyper-proliferative ~~disease, disorder or pathology~~ is selected from the group consisting of psoriasis, scleroderma, epidermal hyperplasia, hyperkeratosis, acanthosis, papilloma, and actinic keratoses, ~~and skin cancer~~ provided that when the disorder is psoriasis, the cyclic psychotropic agent is not atomoxetine.

Claim 64-69. (Cancelled)